(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Some gifted dogs can learn new toy names by eavesdropping on owners - 2McDonald's is bringing two 'KPop Demon Hunters' meals to McDonald's. Here's what they include and when they launch.
- 3Satellite space quiz: What's orbiting Earth?
- 4The most effective method to Shake Hands Expertly: A Bit by bit Guide
- 5Artemis moon mission breaks record for distance from Earth
- This Is Canada's Only Province Without Any Bears
- What's the Fate of 5G Innovation?
- A single shot of HPV vaccine may be enough to fight cervical cancer, study finds
- How to watch 'A Charlie Brown Christmas' for free in 2025
- Hilary Duff announces new album ‘Luck… or Something,’ her first in over 10 years: ‘Excited is the largest understatement’
- Illegal entries into Germany halve over two years, border police say
- Scientists solve the mystery of 'impossible' merger of 'forbidden' black holes
- Step by step instructions to Contrast Lab Precious stones and Normal Jewels
- Baby takes 1st steps after receiving groundbreaking gene-edited therapy
